Inactive Instrument

Highlights Strongbridge Biopharma

Equities

SBBP

IE00BYZ5XL97

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc from HealthCap VI L.P., a fund managed by Odlander, Fredrikson & Co. AB, Caxton Alternative Management LP, and others.	21-10-04	CI
Xeris Pharmaceuticals : Shareholders Approve Pending Strongbridge Biopharma Acquisition	21-09-15	MT
Strongbridge Biopharma : Says Glass Lewis Recommends Shareholders Vote in Favor of Proposed Deal with Xeris	21-08-31	MT
Xeris Pharmaceuticals : ISS Recommends Xeris, Strongbridge Shareholders Vote in Favor of Proposed Deal	21-08-30	MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Reports Q2 Loss $-0.07, vs. Street Est of $-0.10	21-08-05	MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Posts Q2 Revenue $10M, vs. Street Est of $8.89M	21-08-05	MT
Strongbridge Biopharma plc Revises KEVEYIS Revenue Guidance for the Full Year 2021	21-08-05	CI
Strongbridge Biopharma : Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue	21-07-29	AQ
Strongbridge Biopharma plc Announces Publication of Long-Term Efficacy and Safety Results for Keveyis® (Dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve	21-07-13	CI
Strongbridge Biopharma : Receives US Patent for Treating Cushing's Syndrome with Recorlev in Certain Diabetics	21-06-03	MT
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome	21-06-03	CI
Xeris Pharmaceuticals : to Buy Strongbridge Biopharma in $267 Million Deal	21-05-24	MT
Xeris Pharmaceuticals, Inc. entered into a definitive agreement to acquire Strongbridge Biopharma plc from HealthCap VI L.P., a fund managed by Odlander, Fredrikson & Co. AB, Caxton Alternative Management LP, and others for approximately $180 million.	21-05-23	CI
Strongbridge Biopharma plc Announces U.S. Food & Drug Administration Filing Acceptance of New Drug Application for RECORLEV	21-05-13	CI
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Reports Q1 Loss $-0.11, vs. Street Est of $-0.10	21-05-12	MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Posts Q1 Revenue $8.4M, vs. Street Est of $8.31M	21-05-12	MT
Strongbridge Biopharma plc Reiterates Revenue Guidance for the Full Year 2021	21-05-12	CI
Strongbridge Biopharma plc Awaits Day 74 Letter from U.S. Food & Drug Administration for the Company’s New Drug Application Submission for RECORLEV	21-05-12	CI
Strongbridge Biopharma plc Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-12	CI
Strongbridge Biopharma Plc, Announces That Results from Subanalysis of Patients with Diabetes Mellitus from the Phase 3 Sonics Study of RECORLEV	21-04-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Strongbridge Biopharma

Equities

SBBP

IE00BYZ5XL97

Highlights

Filters